The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files, and the published studies are available on the the Malaria in Pregnancy (MiP) Library (<http://library.mip-consortium.org>), the Global Health Database (<http://www.ebscohost.com/corporate-research/global-health>), and the International Network for Rational Use of Drugs (INRUD) Bibliography (<http://www.inrud.org/Bibliographies/INRUD-Bibliography.cfm>).

Introduction {#s2}
============

Malaria in pregnancy is an important public health problem for both maternal and neonatal health programmes. The manifestation of maternal infection with malaria depends on transmission intensity, and prompt diagnosis and treatment of malaria illness in pregnancy is important in all malaria endemic regions. Since 2006, WHO recommends quinine plus clindamycin for the treatment of uncomplicated malaria in the first trimester, and artesunate (AS) plus clindamycin for treatment failures. Artemisinin-based combination therapies (ACTs) known to be effective in the country/region, or AS plus clindamycin, are the recommended combinations for case management of uncomplicated malaria in the second and third trimesters [@pmed.1001688-World1],[@pmed.1001688-World2]. Use of the artemisinin class of compounds, alone or in combination therapies, is not recommended in the first trimester of pregnancy because of insufficient safety data in early pregnancy in humans [@pmed.1001688-Ward1], unless this is the only treatment immediately available [@pmed.1001688-World1].

Many countries in high transmission settings have made ACTs available free of charge to pregnant women in efforts to achieve universal coverage [@pmed.1001688-Roll1]. Despite increasing availability of ACTs and new diagnostic tools, such as rapid diagnostic tests (RDTs), very little is known about women\'s access to these interventions and about the diagnosis and treatment practices of healthcare providers. National malaria indicator surveys focus on access to case management among children, the other important risk group for malaria. Similarly, research on uptake of new diagnostics and ACTs has to date focussed on children and non-pregnant adult populations, whereas research on uptake of interventions in pregnancy has predominantly focussed on progress and challenges to the delivery and uptake of preventive interventions, namely, intermittent preventive treatment in pregnancy (IPTp) and insecticide-treated nets [@pmed.1001688-Hill1]. Information on access to and delivery of effective case management of malaria in pregnancy has not yet received the attention it deserves.

We undertook a systematic review of the factors affecting pregnant women\'s access to and health provider adherence to the 2006 WHO policy [@pmed.1001688-World2] on the treatment of malaria in pregnancy globally. Among pregnant women we reviewed treatment-seeking practices for malaria illness---the range of providers visited, the antimalarials used, and the factors affecting their choice of healthcare provider and medicines. We explored adherence to policy among the range of healthcare providers administering antimalarials to pregnant women, the type and quality of diagnostic and case management services offered at the point of care (including consideration of gestational age), and the health system or other factors that affect quality of care.

Methods {#s3}
=======

Search Strategy {#s3a}
---------------

Studies investigating treatment-seeking practices for malaria among pregnant women and healthcare provider case management practices for malaria in pregnancy were identified by searching the Malaria in Pregnancy Library [@pmed.1001688-vanEijk1], the Global Health Database [@pmed.1001688-EBSCO1], and the International Network for the Rational Use of Drugs (INRUD) Bibliography [@pmed.1001688-International1] from 1 January 2006 to 3 April 2014. The Malaria in Pregnancy Library (<http://library.mip-consortium.org>) is a comprehensive bibliographic database created by the Malaria in Pregnancy Consortium that is updated every 4 mo using a standardised protocol to search over 40 sources, including PubMed, Web of Knowledge, and Google Scholar. Searches were run separately for "pregnant women" and "health providers" (see [Table S1](#pmed.1001688.s001){ref-type="supplementary-material"} for search terms), without language restrictions, and both peer-reviewed and grey literature were retrieved.

Study Selection {#s3b}
---------------

Titles and abstracts were reviewed independently for inclusion by two reviewers (J. Hill and L. D′M-G/J. Hoyt). Studies were included if they met the following criteria: (1) study contained data on treatment seeking among women and/or case management practices for malaria in pregnancy, (2) study population included pregnant women and/or healthcare providers, (3) study reported original research data, and (4) study was conducted following the introduction of ACTs for the treatment of uncomplicated malaria in pregnancy in the study country. No restrictions were placed on study design (i.e., quantitative, qualitative, and mixed methods studies), or quality of reporting. Studies limited to knowledge of malaria in pregnancy amongst pregnant women, i.e., without information on practices, were excluded. The Kappa (K) statistic was used as a measure of the inter-rater agreement on study eligibility between reviewers. Discrepancies between reviewers were resolved through discussions with a third reviewer (J. W.) until consensus was reached.

Studies meeting the inclusion criteria were assessed and grouped according to content. Among pregnant women primary outcomes included (1) treatment-seeking practices for malaria, (2) barriers to accessing malaria treatment, and (3) determinants of treatment seeking for malaria. Among healthcare providers primary outcomes were (1) case management practices for malaria in pregnancy, (2) factors affecting malaria case management practices, and (3) determinants of knowledge, diagnosis, and treatment of malaria.

Data Extraction {#s3c}
---------------

Two authors extracted data and appraised the quality and content of included studies. Data for pregnant women or healthcare providers were extracted and analysed separately for description and frequency of practices, barriers/facilitators, and determinants ([Figure 1](#pmed-1001688-g001){ref-type="fig"}). Two authors (J. Hill and L. D′M-G/A. M. v. E/J. Hoyt) extracted quantitative data on the type and frequency of practices from quantitative and mixed methods studies. For pregnant women these quantitative data included the frequency of malaria episodes, sources of treatment, and the resultant treatment achieved, and for healthcare providers the quantitative data included the type and frequency of diagnostic and treatment practices in relation to national drug policy at the time of publication. J. Hill and L. D′M-G/J. Hoyt extracted qualitative and quantitative data on the barriers and facilitators to treatment seeking among pregnant women and case management practices among healthcare providers from qualitative and mixed methods studies. J. Hill and L. D′M-G/J. Hoyt extracted quantitative data on the determinants of treatment seeking and case management practices among pregnant women and healthcare providers, respectively, from quantitative and mixed methods studies. For healthcare providers, determinants of knowledge and practice, and of diagnosis and treatment, were extracted separately. Two authors (J. Hill and L. D′M-G/J. Hoyt) assessed the quality of reporting of individual studies using a checklist of criteria developed a priori based on criteria and methods described in the literature, described previously [@pmed.1001688-Hill1].

![Analysis strategy.](pmed.1001688.g001){#pmed-1001688-g001}

Data Synthesis and Analysis {#s3d}
---------------------------

Narrative synthesis was used to summarise, compare, and contrast the type, range, and frequency of practices from each study evaluating treatment seeking among pregnant women and case management practices among healthcare providers. To make a comparison between national policy and healthcare provider practices by country and region, we used the national or global malaria policy cited in the included studies.

Barriers and facilitators were explored using content analysis with a previously defined thematic framework for pregnant women and healthcare providers [@pmed.1001688-Hill1]. NVivo version 9.2 (QSR International) was used to generate an index of codes, which identified each of the recurring barriers amongst pregnant women and healthcare providers. The themes emerged as all the data were analysed, working cyclically through the studies. Data from the women\'s perspective were categorised into individual, social/cultural/household, environmental, and health system levels. Data from providers were synthesised into a matrix that combined operational levels of individual, organisational, health system, and non-health system levels, together with the six health systems levels of the WHO Health Systems Framework, which include governance/leadership, service delivery, health workforce/human resources, health information systems, finance, and medical products/technologies [@pmed.1001688-Adam1]--[@pmed.1001688-World3].

We appraised the quality of reporting of each study using a checklist of criteria based on methods described in a previous review [@pmed.1001688-Hill1], as described and reported in [Tables S2](#pmed.1001688.s002){ref-type="supplementary-material"}--[S4](#pmed.1001688.s004){ref-type="supplementary-material"}.

Statistical Analysis {#s3e}
--------------------

We pooled the frequency data for source of treatment among pregnant women and adherence to treatment policy among healthcare providers across different types of providers using random effect meta-analysis in Stata version 12 (StataCorp) and Comprehensive Meta-Analysis (Biostat; <http://www.meta-analysis.com/>), which was also used for sub-group analysis. We used forest plots to visualise the extent of heterogeneity between studies. For studies that reported source of treatment for more than one episode of fever, we included the response to the first episode [@pmed.1001688-Maiga1]. For source of treatment among pregnant women, we conducted sub-group analysis within each category for the following: whether the question involved practice (i.e., women with fever) or attitude (i.e., a hypothetical question, "if they had fever..."); health facility-- or population-based enrolment; urban or rural populations; and country of study (Nigeria, the country contributing the majority of studies, versus other countries). For adherence to treatment policy, we conducted sub-group analysis for the following: trimester treated, the effect of staff cadre (medical doctor versus others), and method of data collection (self-administered questionnaire, interview, or record review). *I* ^2^ was used to quantify heterogeneity [@pmed.1001688-Deeks1].

Results {#s4}
=======

Of 2,047 records retrieved from the database searches, 37 studies met the inclusion criteria ([Figure 2](#pmed-1001688-g002){ref-type="fig"})---13 studies in pregnant women, 18 studies in healthcare providers, and six studies in both pregnant women and healthcare providers; only one study evaluated interventions. There was close agreement between the reviewers on the review of full text articles (K = 0.84). The majority of studies were conducted in Africa (30), with only four studies conducted in Asia (two in India [@pmed.1001688-Sabin1],[@pmed.1001688-Wylie1] and two in Cambodia [@pmed.1001688-Population1],[@pmed.1001688-Tawfik1]), one in Yemen [@pmed.1001688-BinGhouth1], and two in Brazil [@pmed.1001688-Luz1],[@pmed.1001688-Luz2]. Of the studies conducted in Africa, 17 were in west and central Africa and 12 in east and southern Africa, and one study had sites in east, west and southern Africa [@pmed.1001688-Pell1]. All but three studies were cross-sectional surveys at the population or facility level. The remaining studies included two longitudinal qualitative studies [@pmed.1001688-Pell1],[@pmed.1001688-Launiala1] and a randomised controlled trial [@pmed.1001688-SmithPaintain1]. The study characteristics are provided in [Tables 1](#pmed-1001688-t001){ref-type="table"}--[3](#pmed-1001688-t003){ref-type="table"}.

![PRISMA chart of studies included in the review.](pmed.1001688.g002){#pmed-1001688-g002}

10.1371/journal.pmed.1001688.t001

###### Characteristics of studies reporting outcomes, barriers, and determinants for treatment-seeking practices among pregnant women (13 studies).

![](pmed.1001688.t001){#pmed-1001688-t001-1}

  Study Description                                     Primary Outcomes                                                                                                                                 
  ---------------------------------------------------- ------------------ ---------- -------------- ------------- ------------- ------------ ----------------- -------------- ---------- ------- --- --- ---
  Adam 2008 [@pmed.1001688-Adam2]                         East Africa       Sudan      1 district       Rural         2006       Population   Cross-sectional   Quantitative      PW       168    √   √  
  Enato 2009 [@pmed.1001688-Enato1]                       West Africa      Nigeria      1 state         Urban         2005        Facility    Cross-sectional   Quantitative      PW       630    √   √  
  Henry 2012 [@pmed.1001688-Henry1]                       East Africa       Uganda     1 district     IDP camps    2007--2008    Population   Cross-sectional   Quantitative      PW       769    √       √
  Karunamoorthi 2010 [@pmed.1001688-Karunamoorthi1]       East Africa      Ethiopia   \<1 district      Urban         2008        Facility    Cross-sectional   Quantitative      PW       225    √   √  
  Launiala 2010 [@pmed.1001688-Launiala1]               Southern Africa     Malawi    \<1 district      Rural      2002 + 2006    Facility     Longitudinal     Qualitative    Women/PW   34/8    √   √  
  Maiga 2010 [@pmed.1001688-Maiga1]                       West Africa        Mali     \<1 district      Rural          ---        Facility    Cross-sectional   Quantitative      PW       210    √   √  
  Mbachu 2012 [@pmed.1001688-Mbachu1]                     West Africa      Nigeria     1 district       Rural         2011       Population   Cross-sectional   Quantitative      PW       898    √   √   √
  Mbonye 2013 [@pmed.1001688-Mbonye1]                     East Africa       Uganda     1 district    Rural/urban      2011        Facility    Cross-sectional   Quantitative      PW       998    √      
  Onwujekwe 2013 [@pmed.1001688-Onwujekwe1]               West Africa      Nigeria    \<1 district      Urban          ---        Facility    Cross-sectional   Quantitative      PW       647    √      
  Sabin 2010 [@pmed.1001688-Sabin1]                           Asia          India       1 state      Rural/urban      2007        Facility    Cross-sectional      Mixed       PW/RD 12    73     √   √  
  Sam-Wobo 2008 [@pmed.1001688-SamWobo1]                  West Africa      Nigeria     1 district    Rural/urban      2006       Population   Cross-sectional   Quantitative      PW      1,400   √   √  
  Sangaré 2011 [@pmed.1001688-Sangar1]                    East Africa       Uganda    \<1 district   Rural/urban   2008--2009    Population   Cross-sectional   Quantitative      PW       500    √   √   √
  Smith Paintain 2010 [@pmed.1001688-SmithPaintain1]      West Africa       Ghana     2 districts       Rural         2009        Facility          RCT         Qualitative       PW      1,486       √  

PW, pregnant women; RCT, randomised controlled trial; RD 12, recently delivered women (last 12 mo).

10.1371/journal.pmed.1001688.t002

###### Characteristics of studies reporting outcomes, barriers, and determinants for case management practices among healthcare providers (18 studies).

![](pmed.1001688.t002){#pmed-1001688-t002-2}

  Study Description                                     Primary Outcomes                                                                                                                                                               
  ---------------------------------------------------- ------------------ ---------- -------------- ------------- ------------ ------------ ----------------- -------------- --------------------------------------- ----- --- --- --- ---
  Enato 2012 [@pmed.1001688-Enato2]                       West Africa      Nigeria    \<1 district      Urban         ---       Population   Cross-sectional   Qualitative                     TBA                     8    √   √   √  
  Bin Ghouth 2013 [@pmed.1001688-BinGhouth1]              Middle East       Yemen     11 districts      Urban      2010--2011    Facility     Before-after     Quantitative                 Pharm/HP                  86        √   √   √
  Harrison 2012 [@pmed.1001688-Harrison1]                 West Africa      Nigeria     1 district       Urban         2009       Facility    Cross-sectional   Quantitative                    MD                     123   √   √   √   √
  Kalilani-Phiri 2011 [@pmed.1001688-KalilaniPhiri1]    Southern Africa     Malawi      National     Rural/urban      2010      Population   Cross-sectional   Quantitative                 MD/pharm                  92    √       √  
  Kiningu 2013 [@pmed.1001688-Kiningu1]                   East Africa       Kenya     \<1 district      Urban         2012       Facility    Cross-sectional      Mixed                  MD/nurse/pharm               36    √   √   √   √
  Luz 2013 [@pmed.1001688-Luz2]                          South America      Brazil     1 district       Urban      2007--2008    Facility    Cross-sectional      Mixed                  MD/nurse/pharm               51        √   √  
  Luz 2013 [@pmed.1001688-Luz1]                          South America      Brazil    \>1 district      Urban      2007--2008    Facility    Cross-sectional   Quantitative   PW+HP[§](#nt102){ref-type="table-fn"}   262       √       √
  Minyaliwa 2012 [@pmed.1001688-Minyaliwa1]             Southern Africa     Malawi     1 district       Urban         ---        Facility    Cross-sectional   Quantitative      Pharma/nurse/pharma technician       22        √   √  
  Okonta 2011 [@pmed.1001688-Okonta1]                     West Africa      Nigeria      National     Rural/urban      2008      Population   Cross-sectional   Quantitative                    MD                     102       √   √  
  Okoro 2012 [@pmed.1001688-Okoro1]                       West Africa      Nigeria    \<1 district      Urban         2009       Facility    Cross-sectional   Quantitative                    MD                     311   √   √   √  
  Omo-Aghoja 2008 [@pmed.1001688-OmoAghoja1]              West Africa      Nigeria      National     Rural/urban      2006       Facility    Cross-sectional   Quantitative                    MD                     84    √   √   √   √
  Onwujekwe 2012 [@pmed.1001688-Onwujekwe2]               West Africa      Nigeria    \<1 district      Urban         2010       Facility    Cross-sectional   Quantitative              MD/nurse/pharm               52    √   √   √   √
  PSI 2007 [@pmed.1001688-Population1]                        Asia         Cambodia     National     Rural/urban      2007       Facility    Cross-sectional      Mixed           MD/MA/pharm/nurse/midwife/DV        750   √       √  
  Smith Paintain 2011 [@pmed.1001688-SmithPaintain2]      West Africa       Ghana     7 districts       Rural         2009       Facility    Cross-sectional      Mixed                 Midwife/nurse/CHW             134       √   √   √
  Stangeland 2011 [@pmed.1001688-Stangeland1]             East Africa       Uganda    \<1 district      Rural         2009      Population   Cross-sectional      Mixed                        TBA                    28    √       √  
  Tawfik 2006 [@pmed.1001688-Tawfik1]                         Asia         Cambodia   2 districts       Urban         2004      Population   Cross-sectional      Mixed                     Pharm/DV                  70    √   √   √  
  Umar 2011 [@pmed.1001688-Umar1]                         West Africa      Nigeria      1 state         Urban         ---        Facility    Cross-sectional   Quantitative                    FHW                    25    √   √   √   √
  Wylie 2010 [@pmed.1001688-Wylie1]                           Asia          India       2 states     Rural/urban   2006--2008    Facility    Cross-sectional   Quantitative   PW+HP[†](#nt103){ref-type="table-fn"}   280   √       √   √

Health provider practices inferred from medical file/ANC card.

Health provider practices observed.

CHW, community health worker; DV, drug vendor/drug store; FHW, female health worker; HP, health provider; MA, medical assistant; MD, medical doctor; pharm, pharmacist (trained); PSI, Population Services International Research and Metrics; PW, exit interviews with pregnant women.

10.1371/journal.pmed.1001688.t003

###### Characteristics of studies reporting outcomes for both pregnant women and health providers (six studies).

![](pmed.1001688.t003){#pmed-1001688-t003-3}

  Study Description                                               *N*               Primary Outcome (PW/HP)[\*](#nt105){ref-type="table-fn"}                                                                                                                                                                         
  -------------------------------------------------- ----------------------------- ---------------------------------------------------------- -------------- ------------- ------------ ------------ ----------------- -------------- ---------------------------------------- ------- ----- --- --- --- --- --- --- ---
  Kamuhabwa 2011 [@pmed.1001688-Kamuhabwa1]                   East Africa                                   Tanzania                           \<1 district      Urban      2009--2010    Facility    Cross-sectional   Quantitative                   PW+DV                     200    200       √   √       √   √   √
  Kwansa-Bentum 2011 [@pmed.1001688-KwansaBentum1]            West Africa                                    Ghana                              1 district    Rural/urban      2010      Population   Cross-sectional   Quantitative             PW+MD/nurse/pharm               959    126   √   √           √   √  
  Manirakiza 2011 [@pmed.1001688-Manirakiza1]               Central Africa                                    CAR                              \<1 district      Urban         2009       Facility    Cross-sectional   Quantitative   PW+HP[§](#nt106){ref-type="table-fn"}     565              √       √   √   √  
  Mbonye 2010 [@pmed.1001688-Mbonye2]                         East Africa                                    Uganda                             1 district    Rural/urban      ---       Population   Cross-sectional   Quantitative               PW+TBA/DV/CHW                2,785   51        √               √  
  Obieche 2013 [@pmed.1001688-Obieche1]                       West Africa                                   Nigeria                            \<1 district      Urban         2011       Facility    Cross-sectional   Quantitative   PPW+HP[§](#nt106){ref-type="table-fn"}    428          √           √   √      
  Pell 2013 [@pmed.1001688-Pell1]                     East, west, southern Africa                     Kenya, Ghana, Malawi                     4 districts    Rural/urban   2009--2011   Population   Anthropological   Qualitative                    PW+HP                     390    137       √               √  

\*Primary outcomes for both pregnant women and health providers: (1) treatment-seeking practices, (2) barriers to treatment seeking, (3) determinants of treatment seeking, (4) knowledge and practices for case management of malaria (diagnosis/treatment), (5) barriers to case management, and (6) determinants of case management.

Health provider practices inferred from medical file/ANC card.

CHW, community health worker; D, diagnostics; DV, drug vendor/drug store; HP, health provider; MD, medical doctor; pharm, pharmacist (trained); PPW, postpartum women; PW, pregnant women; T, treatment.

Quality of about half (14/27) of the quantitative studies was assessed to be moderate-high (scored 6--8/10), with ten low-moderate-quality studies (4--5/10) and three high-quality studies (9--10/10) ([Table S2](#pmed.1001688.s002){ref-type="supplementary-material"}). The quality criterion least often met among these studies was the use of multivariate analysis. The four qualitative studies were assessed as moderate-high quality (4--7/8), with only one of the studies reporting saturation of themes ([Table S3](#pmed.1001688.s003){ref-type="supplementary-material"}). All six mixed methods studies were assessed as high quality (9--10/11), though only one study reported use of multivariate analysis ([Table S4](#pmed.1001688.s004){ref-type="supplementary-material"}). Data on frequencies of practices, barriers/facilitators, and determinants of access among women were extracted from 13, 15, and four studies, respectively, and of policy adherence among healthcare providers, from 24, 22, and ten studies, respectively ([Table 4](#pmed-1001688-t004){ref-type="table"}).

10.1371/journal.pmed.1001688.t004

###### Data extracted for frequencies, barriers, and determinants by survey type.

![](pmed.1001688.t004){#pmed-1001688-t004-4}

  Study                                                 Pregnant Women[†](#nt108){ref-type="table-fn"}   Healthcare Providers[≠](#nt109){ref-type="table-fn"}                
  ---------------------------------------------------- ------------------------------------------------ ------------------------------------------------------ --- ---- ---- ----
  **Facility-based studies**                                                                                                                                                 
  Bin Ghouth 2013 [@pmed.1001688-BinGhouth1]                                                                                                                        √    √    √
  Kiningu 2013 [@pmed.1001688-Kiningu1]                                                                                                                             √    √    √
  Luz 2013 [@pmed.1001688-Luz1]                                                                                                                                     √         √
  Luz 2013 [@pmed.1001688-Luz2]                                                                                                                                     √    √   
  Mbonye 2013 [@pmed.1001688-Mbonye1]                                                                                                                               √        
  Obieche 2013 [@pmed.1001688-Obieche1]                                       √                                                                                     √        
  Onwujekwe 2013 [@pmed.1001688-Onwujekwe1]                                   √                                                                                     √        
  Harrison 2012 [@pmed.1001688-Harrison1]                                                                                                                           √    √    √
  Minyaliwa 2012 [@pmed.1001688-Minyaliwa1]                                                                                                                         √    √   
  Okoro 2012 [@pmed.1001688-Okoro1]                                                                                                                                 √    √   
  Onwujekwe 2012 [@pmed.1001688-Onwujekwe2]                                                                                                                         √    √    √
  Kamuhabwa 2011 [@pmed.1001688-Kamuhabwa1]                                   √                                                   √                             √   √    √    √
  Manirakiza 2011 [@pmed.1001688-Manirakiza1]                                                                                     √                                 √    √   
  Smith Paintain 2011 [@pmed.1001688-SmithPaintain2]                                                                                                                √    √    √
  Umar 2011 [@pmed.1001688-Umar1]                                                                                                                                   √    √    √
  Karunamoorthi 2010 [@pmed.1001688-Karunamoorthi1]                           √                                                   √                                          
  Launiala 2010 [@pmed.1001688-Launiala1]                                                                                         √                                          
  Maiga 2010 [@pmed.1001688-Maiga1]                                           √                                                   √                                          
  Sabin 2010 [@pmed.1001688-Sabin1]                                           √                                                   √                                          
  Smith Paintain 2010 [@pmed.1001688-SmithPaintain1]                                                                              √                                          
  Wylie 2010 [@pmed.1001688-Wylie1]                                                                                                                                 √    √    √
  Enato 2009 [@pmed.1001688-Enato1]                                           √                                                   √                                          
  Omo-Aghoja 2008 [@pmed.1001688-OmoAghoja1]                                                                                                                        √    √    √
  PSI 2007 [@pmed.1001688-Population1]                                                                                                                              √    √   
  **Population-based studies**                                                                                                                                               
  Pell 2013 [@pmed.1001688-Pell1]                                                                                                 √                                      √   
  Enato 2012 [@pmed.1001688-Enato2]                                                                                                                                 √    √   
  Mbachu 2012 [@pmed.1001688-Mbachu1]                                         √                                                   √                             √            
  Henry 2012 [@pmed.1001688-Henry1]                                           √                                                                                 √            
  Kalilani-Phiri 2011 [@pmed.1001688-KalilaniPhiri1]                                                                                                                √    √   
  Kwansa-Bentum 2011 [@pmed.1001688-KwansaBentum1]                            √                                                   √                                 √    √   
  Okonta 2011 [@pmed.1001688-Okonta1]                                                                                                                               √    √   
  Sangaré 2011 [@pmed.1001688-Sangar1]                                        √                                                   √                             √            
  Stangeland 2011 [@pmed.1001688-Stangeland1]                                                                                                                       √    √   
  Mbonye 2010 [@pmed.1001688-Mbonye2]                                                                                             √                                      √   
  Adam 2008 [@pmed.1001688-Adam2]                                             √                                                   √                                          
  Sam-Wobo 2008 [@pmed.1001688-SamWobo1]                                      √                                                   √                                          
  Tawfik 2006 [@pmed.1001688-Tawfik1]                                                                                                                               √    √   
  Summary total                                                               13                                                  15                            4   24   22   10

Pregnant women: for frequency data, see [Tables 5](#pmed-1001688-t005){ref-type="table"} and [6](#pmed-1001688-t006){ref-type="table"}; barrier data, [Table 7](#pmed-1001688-t007){ref-type="table"}; determinant data, [Table 8](#pmed-1001688-t008){ref-type="table"}.

Healthcare provider: for frequency data, see [Tables 9](#pmed-1001688-t009){ref-type="table"} and [10](#pmed-1001688-t010){ref-type="table"}; barrier data, [Table 11](#pmed-1001688-t011){ref-type="table"}; determinant data, [Table 12](#pmed-1001688-t012){ref-type="table"}.

PSI, Population Services International Research and Metrics.

Pregnant Women Perspectives {#s4a}
---------------------------

The 19 studies that contributed data on the treatment-seeking practices of pregnant women were undertaken in ten countries across Africa (seven studies in east Africa, eight in west Africa, one in southern Africa, one in central Africa, and one with sites in east, west, and southern Africa) and in one country in Asia ([Tables 1](#pmed-1001688-t001){ref-type="table"} and [3](#pmed-1001688-t003){ref-type="table"}).

### Description and frequency of practices among pregnant women {#s4a1}

The proportion of women reporting at least one episode of malaria during their current or recent pregnancy ranged from 25% to 75% of respondents in three population-based [@pmed.1001688-Mbachu1]--[@pmed.1001688-Henry1] and three facility-based [@pmed.1001688-Sabin1],[@pmed.1001688-Enato1],[@pmed.1001688-Obieche1] studies in Africa and Asia, with between 30% and 46% of women reporting two or more episodes in Africa [@pmed.1001688-Sangar1],[@pmed.1001688-Enato1],[@pmed.1001688-Obieche1] ([Tables 5](#pmed-1001688-t005){ref-type="table"} and [6](#pmed-1001688-t006){ref-type="table"}). Of one population-based [@pmed.1001688-Sangar1] and three facility-based [@pmed.1001688-Sabin1],[@pmed.1001688-Obieche1],[@pmed.1001688-Onwujekwe1] studies, a high proportion (\>85%) of women with a reported episode of malaria during pregnancy sought some form of treatment.

10.1371/journal.pmed.1001688.t005

###### Symptoms and number of episodes of malaria in pregnancy, and percentage who sought treatment by source, reported by pregnant women: population-based studies.
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  Region                          Country                        Study                            Scale        *N*    Reported an Episode of Malaria in Pregnancy                   Number of Episodes Reported per Pregnancy                    Percentage of Women Who Sought Treatment            Source of Treatment                                                                  
  ------------------------------ --------- -------------------------------------------------- -------------- ------- --------------------------------------------- ---------------------------------------------------------------------------- ------------------------------------------ --------------------------------------- ------- --------------------------------------- ------ ---------------------------------------
  **West and Central Africa**      Ghana    Kwansa-Bentum 2011 [@pmed.1001688-KwansaBentum1]    1 district     959                        NR                                                            NR                                                          NR                                      25.4%                           28.8%[§](#nt111){ref-type="table-fn"}          5.4%[†](#nt112){ref-type="table-fn"}
                                  Nigeria         Mbachu 2012 [@pmed.1001688-Mbachu1]           1 district     898                   25.3% (fever)                                                      NR                                                          NR                                      42.3%                                                                         
                                  Nigeria        Sam-Wobo 2008 [@pmed.1001688-SamWobo1]         1 district    1,400                       NR                        65.0% of PW had 3--4 episodes of malaria that year (not current pregnancy)                      NR                                                                                                                     68.0%[∞](#nt113){ref-type="table-fn"}
  **East and Southern Africa**     Sudan            Adam 2008 [@pmed.1001688-Adam2]             1 district     168                        NR                                                            NR                                                          NR                      81.5%[∧](#nt114){ref-type="table-fn"}                                                   9.5%  
                                  Uganda           Henry 2012 [@pmed.1001688-Henry1]            1 district     769                49.0% in past 2 mo                                                    NR                                                          NR                      86.0%[¢](#nt115){ref-type="table-fn"}   10.0%                   4.0%                          
                                  Uganda          Sangaré 2011 [@pmed.1001688-Sangar1]         \<1 district    500                       66.8%                                    37.0% had 2+ episodes of malaria in pregnancy                          94% of reported episodes                                                                                                         

Multiple response answers.

Herbs; \<1% sought prayers, baths, water, and/or sleep.

Specified as herbs.

8.9% specifically sought a midwife.

IDP camp setting.

HCF, healthcare facility; NR, not reported by study authors; PW, pregnant women.

10.1371/journal.pmed.1001688.t006

###### Symptoms and number of episodes of malaria in pregnancy, and percentage who sought treatment by source, reported by pregnant women: facility-based studies.

![](pmed.1001688.t006){#pmed-1001688-t006-6}

  Region                          Country                          Study                            Scale                       *N*                   Percentage of Women Who Reported an Episode of Malaria in Pregnancy       Number of Episodes Reported per Pregnancy        Percentage of Women Who Sought Treatment    Source of Treatment                     
  ------------------------------ ---------- --------------------------------------------------- -------------- ------------------------------------- --------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------- --------------------- ---------- ------- ---------------------------------------
  **West and Central Africa**       Mali             Maiga 2010 [@pmed.1001688-Maiga1]           \<1 district                   210                                                   NR                                                            NR                                              NR                              31.4%                     40.0%                   27.6%
                                  Nigeria          Obieche 2013 [@pmed.1001688-Obieche1]         \<1 district                   428                                                  69.4%                                               30% reported \>1 episode                       84.6% of reported episodes                  77.4%           10.7%     12.0%  
                                  Nigeria        Onwujekwe 2013 [@pmed.1001688-Onwujekwe1]       \<1 district                   647                                                   NR                                                            NR                           Women attending public facilities, 95.3%           89.1%            5.7%     5.2%   
                                                                                                                                                                                                                                                                                 Women attending private facilities, 98.6%          92.0%            2.3%     6.0%   
                                  Nigeria            Enato 2009 [@pmed.1001688-Enato1]             1 state                      630                                                  64.1%                                  1 episode, 53.7%; 2, 27.3%; 3, 6.3%; and 4+, 12.7%                      NR                              78.0%                     22.0%  
  **East and Southern Africa**    Ethiopia   Karunamoorthi 2010 [@pmed.1001688-Karunamoorthi1]   \<1 district                   225                                                   NR                                                            NR                                              NR                              88.1%                     7.4%    4.5%[α](#nt117){ref-type="table-fn"}
                                   Malawi         Launiala 2010 [@pmed.1001688-Launiala1]        \<1 district                   34                                                    NR                                                            NR                                              NR                          Second choice      Majority          
  **Asia**                         India             Sabin 2010 [@pmed.1001688-Sabin1]             1 state      73[\*](#nt118){ref-type="table-fn"}                                  75.0%                                                          NR                                  85.0% of reported episodes                  63.0%                     20.8%   16.7%[¥](#nt119){ref-type="table-fn"}

Specified as TBA.

\*Pregnant women and recently delivered women.

Specified as traditional remedies.

HCF, healthcare facility; NR, not reported by authors.

Pregnant women in three population-based [@pmed.1001688-Henry1],[@pmed.1001688-KwansaBentum1],[@pmed.1001688-Adam2] and seven facility-based [@pmed.1001688-Maiga1],[@pmed.1001688-Sabin1],[@pmed.1001688-Launiala1],[@pmed.1001688-Enato1]--[@pmed.1001688-Onwujekwe1],[@pmed.1001688-Karunamoorthi1] studies in Africa reported self-medication or treatment at a pharmacy/drug store at the onset of fever (range 5%--40%), and attended a health facility only if their fever did not respond to this treatment [@pmed.1001688-Maiga1],[@pmed.1001688-KwansaBentum1] ([Tables 5](#pmed-1001688-t005){ref-type="table"} and [6](#pmed-1001688-t006){ref-type="table"}). In southern Ghana, women seeking treatment at a pharmacy or drug vendor without a clinic prescription reported that the antimalarials were selected by either the shop attendant (21% and 26% in rural and urban areas, respectively) or themselves (8% and 10%, respectively) [@pmed.1001688-KwansaBentum1]. Use of local herbs was a first resort among pregnant women in a population-based study in Nigeria [@pmed.1001688-SamWobo1]. Pregnant women in urban settings were likely to seek care from antenatal care (ANC) or health facilities as a first resort, as observed in three population-based studies in Nigeria (42%) [@pmed.1001688-Mbachu1], Sudan (82%) [@pmed.1001688-Adam2], and internally displaced person (IDP) camps in Uganda (86%) [@pmed.1001688-Henry1], and five facility-based studies (range 63%--92%) in Ethiopia [@pmed.1001688-Karunamoorthi1], Nigeria [@pmed.1001688-Enato1]--[@pmed.1001688-Onwujekwe1], and India [@pmed.1001688-Sabin1].

Data on sources of treatment extracted from nine studies showed high heterogeneity across studies (*I* ^2^ ranging from 60% to 99%) ([Figure 3](#pmed-1001688-g003){ref-type="fig"}), and all but one study [@pmed.1001688-Maiga1] were of moderate to high quality. Site of enrolment (health facility-- versus population-based), country (Nigeria versus other countries), and type of question (practice versus attitude) had no effect within each category ([Table S5](#pmed.1001688.s005){ref-type="supplementary-material"}). Compared to urban women, rural women were more likely to make use of a traditional healer or herbs (2%, 95% CI 0%--7%, three studies, versus 21%, 95% CI 6%--52%, four studies, respectively, *p* = 0.008), whereas urban women made more use of health facilities (84%, 95% CI 71%--91%, two studies, versus 38%, 95% CI 14%--70%, four studies, *p* = 0.006).

![Prevalence of source of malaria treatment during pregnancy assessed in 18 studies with quantitative data.\
hf, health facility--based survey; pb, population-based survey.](pmed.1001688.g003){#pmed-1001688-g003}

Only six of the 14 studies among pregnant women with treatment-seeking practice as a primary outcome included quantitative data on use of ACTs, and of these, only four stratified use by trimester. In a household survey in Uganda, among first trimester episodes, quinine was used in only 6% of first trimester cases, with \>80% of episodes treated with drugs not recommended for use in the first trimester either because they are contraindicated (sulphadoxine-pyrimethamine \[SP\] and artemether-lumefantrine \[AL\]) or because of high-grade drug resistance (chloroquine \[CQ\]) [@pmed.1001688-Sangar1]. Only 30% of second and third trimester cases adhered to national guidelines (AL or quinine) [@pmed.1001688-Sangar1]. Another study conducted in 2011 in Uganda reported appropriate treatment in only 36% of febrile cases, defined as parasite-positive pregnant women given AL (Coartem) and parasite-negative women given no antimalarial drug [@pmed.1001688-Mbonye1]. Of pregnant women interviewed at a public hospital in Tanzania, 31% had used AL for an episode of malaria in the index pregnancy, 27% SP, 23% quinine, 16% sulphalene-pyrimethamine, and 3% amodiaquine (AQ) [@pmed.1001688-Kamuhabwa1]. The majority (82%) of women said they were asked about gestational age before being given AL by drug dispensers; however, only 17% of pregnant women were aware that AL should not be taken in the first trimester, and only 22% knew that quinine was recommended. In a population-based study in Ghana, drug sellers said some women requested artemisinin combinations for treatment in the first trimester [@pmed.1001688-KwansaBentum1].

A household survey in southeast Nigeria found that 42% of pregnant women who had a fever within the last month had visited a health facility, of which 46% were treated with ACTs, 34% with SP, and 4% with artemisinin monotherapy; however, trimester was not specified [@pmed.1001688-Mbachu1]. In an earlier population-based study in Nigeria, women reported a high preference for SP for case management in the second and third trimesters of pregnancy, whereas the national treatment policy in second and third trimesters was to use AL; the study was, however, done only a year after the new policy was introduced [@pmed.1001688-SamWobo1]. A more recent facility-based study in a teaching hospital reported that quinine was used in only 12% of first trimester episodes, with artemisinin-containing compounds, SP, and CQ used in 35%, 39%, and 14% of cases, respectively [@pmed.1001688-Obieche1]. In a comparative study of treatment practices of second and third trimester episodes in public and private health facilities, quinine was used in 4% of episodes in both types of facility, with artemisinin monotherapy constituting the most frequently prescribed drug (36%--39%) [@pmed.1001688-Onwujekwe1].

### Barriers to care seeking for malaria among pregnant women {#s4a2}

The factors affecting treatment seeking for malaria most frequently cited in the content analysis related to the following: women\'s knowledge and perceptions of risk, perceptions and experience of drug safety, cost, and perceptions and experience of healthcare provider and health facility factors ([Table 7](#pmed-1001688-t007){ref-type="table"}). Women in one facility-based study [@pmed.1001688-Sabin1] perceived malaria during pregnancy as not especially dangerous, and the first response in two population-based [@pmed.1001688-KwansaBentum1],[@pmed.1001688-Adam2] and four facility-based [@pmed.1001688-Maiga1],[@pmed.1001688-Sabin1],[@pmed.1001688-Launiala1],[@pmed.1001688-Karunamoorthi1] studies was to rely on self-medication or herbal treatments, and to seek medical advice only if the illness did not improve. Over 50% of women in a facility-based study reported delaying \>2 d after first noticing symptoms before seeking care [@pmed.1001688-Enato1]. The choice of treatment was influenced by women\'s perceptions of the safety of drugs used during pregnancy, as reported by three population-based studies [@pmed.1001688-KwansaBentum1],[@pmed.1001688-Adam2],[@pmed.1001688-SamWobo1] and one facility-based study [@pmed.1001688-Kamuhabwa1]. Fear and/or prior experience of side effects to drugs also influenced treatment choices and adherence, as reported by one population-based [@pmed.1001688-Pell1] and three facility-based [@pmed.1001688-Sabin1],[@pmed.1001688-SmithPaintain1],[@pmed.1001688-Kamuhabwa1] studies. In northern Ghana, pregnant women identified contradictions between messages provided in health facilities and their own experiences of malaria [@pmed.1001688-Pell1].

10.1371/journal.pmed.1001688.t007

###### Content analysis of factors that affect treatment seeking for malaria among pregnant women.

![](pmed.1001688.t007){#pmed-1001688-t007-7}

  Barriers and Facilitators to Treatment Seeking for Pregnant Women         Level                                                                                                                      
  ------------------------------------------------------------------- ----------------- ------------------------------------------------------------------------------------ --- --- --- --- -- -- --- ---
  **Barriers**                                                            Knowledge                         Low perceived danger of malaria in pregnancy                      1   2                    
                                                                                                                Low knowledge of treatment measures                           5   3                    
                                                                                                           Reliance on self-medication/herbal treatments                      5   4                    
                                                                                                     Pregnant women considered less of a priority or vulnerable                       0   1            
                                                                           Safety                          Perception of safety of drugs during pregnancy                     3   1                    
                                                                                                                        Fear of side effects                                  1   3                    
                                                                                                                     Experience of side effects                               0   2                    
                                                                            Cost                                         Cost of treatment                                            4   3            
                                                                                                                Travel costs to health care facility                                  0   3            
                                                                                                                             User fees                                                              2   2
                                                                                                                     Husband controls finances                                        0   1            
                                                                       Health facility                                    Drug stock-outs                                                           1   1
                                                                                         Lack of trust in provider/confusion about healthcare provider advice for treatment   0   1                    
                                                                                                           Lack of adequate care at health care facility                                            0   1
  **Facilitators**                                                        Knowledge                               Concern for status of pregnancy                             0   2                    
                                                                                                                   Awareness of treatment options                             1   2                    
                                                                                                              Trust in health care facility/medication                        0   2                    
                                                                           Safety                                Belief that drugs are safe to use                            2   1                    
                                                                                                                 Treatment considered as effective                            4   3                    
                                                                                                                    Very few or no side effects                               1   0                    

Numbers indicate the number of studies included in this review that report each factor.

qual, qualitative; quan, quantitative.

The high cost of treatment prevented pregnant women from using the formal health sector in rural population-based surveys in Ghana [@pmed.1001688-Pell1],[@pmed.1001688-KwansaBentum1], Kenya [@pmed.1001688-Pell1], and Nigeria [@pmed.1001688-Mbachu1]. Poverty was said to be why women resorted to herbal remedies in Kenya and Ghana, to avoid costs of both transport and medical care [@pmed.1001688-Pell1]. Other barriers cited were user fees at formal health services [@pmed.1001688-SamWobo1] or the cost of treatment in urban areas in population-based surveys in Ghana [@pmed.1001688-KwansaBentum1] and facility-based studies in the Central African Republic (CAR) [@pmed.1001688-Manirakiza1] and India [@pmed.1001688-Sabin1]. Lack of adequate care at health facilities [@pmed.1001688-SmithPaintain1] was an additional deterrent to using the health facilities. Women in one study reported that they did not understand the instructions given by dispensers regarding (AL) dosage and duration of use [@pmed.1001688-Kamuhabwa1]. On the other hand, women who were concerned for their pregnancy status, who were aware of the treatment options [@pmed.1001688-Launiala1],[@pmed.1001688-SmithPaintain1],[@pmed.1001688-KwansaBentum1] and considered the drugs safe and effective [@pmed.1001688-Sabin1],[@pmed.1001688-Sangar1],[@pmed.1001688-KwansaBentum1],[@pmed.1001688-Kamuhabwa1], and who trusted the health facility staff [@pmed.1001688-Pell1],[@pmed.1001688-SmithPaintain1] were more likely to seek treatment at health facilities. Women in Ghana and Kenya generally valued diagnostic tests for malaria (and other diseases) and associated testing with more effective treatment [@pmed.1001688-Pell1].

### Determinants of care seeking for malaria among pregnant women {#s4a3}

The range of determinants of treatment seeking among pregnant women explored across the included studies included education, prior experience of miscarriage, and ANC use. The key findings are highlighted in [Table 8](#pmed-1001688-t008){ref-type="table"}; insufficient data and lack of consistency in the indicators used prevented us from performing a meta-analysis of pooled data. A higher level of education was associated with correct knowledge of AL use in pregnancy in Tanzania [@pmed.1001688-Kamuhabwa1]. Prior use of ANC services and previous experience of miscarriage were associated with increased treatment seeking for malaria in IDP camps in Uganda [@pmed.1001688-Henry1].

10.1371/journal.pmed.1001688.t008

###### Data on the determinants of treatment-seeking behaviours for malaria in pregnancy by pregnant women.
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  Determinant                                    Study                     Country       Scale       *N*                                                          Details
  --------------------------- ------------------------------------------- ---------- -------------- ----- -----------------------------------------------------------------------------------------------------------------------
  Age                          Kamuhabwa 2011 [@pmed.1001688-Kamuhabwa1]   Tanzania   \<1 district   200                                Age is not associated with knowledge of AL use in pregnancy
                                   Henry 2012 [@pmed.1001688-Henry1]        Uganda     1 district    769                                  Age is not associated with increased treatment seeking
  Education                    Kamuhabwa 2011 [@pmed.1001688-Kamuhabwa1]   Tanzania   \<1 district   200      A higher level of education in women was associated with correct knowledge of AL use in pregnancy (*p*\<0.001)
                                   Henry 2012 [@pmed.1001688-Henry1]        Uganda     1 district    769                      Women\'s level of education was not associated with increased treatment seeking
  Marital status                   Henry 2012 [@pmed.1001688-Henry1]        Uganda     1 district    769                             Marital status was not associated to increased treatment seeking
  Parity/gravidity             Kamuhabwa 2011 [@pmed.1001688-Kamuhabwa1]   Tanzania   \<1 district   200                         Parity/gravidity was not associated with knowledge of AL use in pregnancy
                                   Henry 2012 [@pmed.1001688-Henry1]        Uganda     1 district    769                               Gravidity was not associated with increased treatment seeking
                                 Sangaré 2011 [@pmed.1001688-Sangar1]       Uganda     1 district    500   There was no difference between multiparous and primiparous women in their use of the recommended dosage of treatment
  Gestational age              Kamuhabwa 2011 [@pmed.1001688-Kamuhabwa1]   Tanzania    1 district    200                        Age of gestation was not associated with knowledge of AL usage in pregnancy
                                   Henry 2012 [@pmed.1001688-Henry1]        Uganda     1 district    769                           Age of gestation was not associated with increased treatment seeking
  Experience of miscarriage        Henry 2012 [@pmed.1001688-Henry1]        Uganda     1 district    769               Prior experience of miscarriage was associated with increased treatment seeking (*p* = 0.049)
  Prior use of ANC                 Henry 2012 [@pmed.1001688-Henry1]        Uganda     1 district    769             Prior use of ANC services by women was associated with increased treatment seeking (*p* = 0.029)
  SES                             Mbachu 2012 [@pmed.1001688-Mbachu1]      Nigeria     1 district    898             SES of women was not associated with the utilisation of different antimalarials by pregnant women

All effects measured using the Chi-squared test.

SES, socio-economic status.

Healthcare Provider Perspectives {#s4b}
--------------------------------

The 24 studies that contributed data on the diagnosis and treatment practices of healthcare providers were undertaken in ten countries, involving a range of cadres, including medical doctors and nurses, pharmacists, drug vendors, traditional birth attendants (TBAs), and community health workers (CHWs) ([Tables 2](#pmed-1001688-t002){ref-type="table"} and [3](#pmed-1001688-t003){ref-type="table"}).

### Description and frequency of diagnostic practices {#s4b1}

Malaria diagnosis in pregnancy by public healthcare providers in the studies conducted in Africa was predominantly performed on the basis of clinical symptoms, as reported by one population-based study in Ghana [@pmed.1001688-KwansaBentum1] and five facility-based studies in CAR [@pmed.1001688-Manirakiza1] and Nigeria [@pmed.1001688-OmoAghoja1]--[@pmed.1001688-Okoro1]. The exceptions to this were microscopy use by private sector providers in Nigeria [@pmed.1001688-Onwujekwe2] and by a provincial hospital in Kenya [@pmed.1001688-Kiningu1] ([Table 9](#pmed-1001688-t009){ref-type="table"}). One population-based study in Malawi [@pmed.1001688-KalilaniPhiri1] and three facility-based studies in Nigeria [@pmed.1001688-OmoAghoja1],[@pmed.1001688-Umar1],[@pmed.1001688-Harrison1] reported a combination of clinical and parasitological diagnosis by microscopy. Providers at the community level in three population-based studies, including private providers in Cambodia [@pmed.1001688-Tawfik1] and TBAs in Africa [@pmed.1001688-Enato2],[@pmed.1001688-Stangeland1], relied exclusively on clinical symptoms unless women could produce prescriptions issued from clinics. Globally, few studies reported healthcare providers using RDTs. In Africa, reports of RDT use have been relatively recent (2011 in Malawi [@pmed.1001688-KalilaniPhiri1] and 2012 in Nigeria [@pmed.1001688-Onwujekwe2]), compared to in Asia (2007 in Cambodia [@pmed.1001688-Population1]), and only a fraction of providers reported using RDTs (range 22%--34%) [@pmed.1001688-Population1],[@pmed.1001688-Onwujekwe2],[@pmed.1001688-KalilaniPhiri1]. In a population-based survey of medical doctors and pharmacists in Malawi, availability of tests, patient symptoms, and cost were the main factors affecting choice of diagnostic test [@pmed.1001688-KalilaniPhiri1]. In an observational study of ANC visits in eastern India, blood tests were typically obtained if a patient complained of fever, though enquiries into presence of fever in patients were made in only a minority of patients [@pmed.1001688-Wylie1].

10.1371/journal.pmed.1001688.t009

###### Healthcare provider practices: diagnosis.
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  Region                          Country                          Study                                                      Policy Reference                                      Policy Details: Diagnosis            Scale        Reported Provider Practice                                                                                                                                                                                                                                                                                               
  ------------------------------ ---------- --------------------------------------------------- ----------------------------------------------------------------------------- ------------------------------------- ---------------- ---------------------------- ---------------------------------------- ----- --------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------- -----------------------------------------------------------------------------
  **West and Central Africa**     Nigeria          Obieche 2013 [@pmed.1001688-Obieche1]                 National Antimalarial Treatment Guidelines and Policy, 2005                                                 Microscopy/RDT          \<1 district          Medical records and interviews with PW                                                                                                                                                                                                                               8.6%                   
                                  Nigeria         Harrison 2012 [@pmed.1001688-Harrison1]                National Antimalarial Treatment Guidelines and Policy, 2005                      Fever, pallor              Microscopy/RDT           1 district                             MD                     123      85.4%[∧](#nt125){ref-type="table-fn"}                                                                                                                                                              85.4%[∧](#nt125){ref-type="table-fn"}  
                                  Nigeria            Okoro 2012 [@pmed.1001688-Okoro1]                   National Antimalarial Treatment Guidelines and Policy, 2005                      Fever, pallor              Microscopy/RDT          \<1 district                            HP                     311                      80.0%                                                                                                                                                                                              20.0%                  
                                  Nigeria        Onwujekwe 2012 [@pmed.1001688-Onwujekwe2]               National Antimalarial Treatment Guidelines and Policy, 2005                      Fever, pallor              Microscopy/RDT          \<1 district                  Public: MD/nurse/pharm           32       78.1%[§](#nt126){ref-type="table-fn"}                                                                                                                                                                              65.6%                                                      43.8%
                                                                                                                                                                                                                                                                          Private: MD/nurse/pharm           20       47.4%[§](#nt126){ref-type="table-fn"}                                                                                                                                                                              68.4%                                                      15.8%
                                  Nigeria            Enato 2012 [@pmed.1001688-Enato2]                   National Antimalarial Treatment Guidelines and Policy, 2005                      Fever, pallor              Microscopy/RDT          \<1 district                           TBA                      8                      100.0%                                                            Fever, colour of urine, dizziness, blood pressure, weakness, and appetite                                                                                
                                  Nigeria             Umar 2011 [@pmed.1001688-Umar1]                                        WHO guidelines 2010                                     Fever, pallor, anaemia          Microscopy/RDT            1 state                               HP                     25       69.3%[€](#nt127){ref-type="table-fn"}                                                                                                                                                              87.5%[α](#nt128){ref-type="table-fn"}  
                                  Nigeria       Omo-Aghoja 2008 [@pmed.1001688-OmoAghoja1]               National Antimalarial Treatment Guidelines and Policy, 2005                      Fever, pallor              Microscopy/RDT            National                              MD                     84       62.0%[†](#nt129){ref-type="table-fn"}                                                                                                                                                              26.0%[†](#nt129){ref-type="table-fn"}  
  **East and Southern Africa**     Kenya           Kiningu 2013 [@pmed.1001688-Kiningu1]                              National Malaria Guidelines, 2010                                                              Microscopy/RDT          \<1 district                     Medical records               37                       5.5%                                                                                                                                                                                               91.9%                  
                                   Malawi    Kailani-Phiri 2011 [@pmed.1001688-KalilaniPhiri1]                           Malawi ACT guidelines, 2008                                                                                           National                           MD/pharm                  92                       84.1%                                           Used symptoms in addition to lab tests[§](#nt126){ref-type="table-fn"} ^,^ [µ](#nt130){ref-type="table-fn"}                                        73.1%                   25.6%[µ](#nt130){ref-type="table-fn"}/1.20%[¢](#nt131){ref-type="table-fn"}
                                   Uganda       Stangeland 2011 [@pmed.1001688-Stangeland1]      National Malaria Treatment Guidelines, 2005[¥](#nt132){ref-type="table-fn"}        History and physical exam        Microscopy/RDT          \<1 district                           TBA                     28                      100.0%                      75% fever, 75% shivers, 39% headache, 29% vomiting, 25% pale eyes, 25% no appetite, 25% weakness, 21% abdominal pains[§](#nt126){ref-type="table-fn"}                                          
  **Asia**                        Cambodia         PSI 2007 [@pmed.1001688-Population1]                                              NA                                                                                                        National                 MD/MA/pharm/nurse/midwife/DV        750                                                                                                                                                                                                                                                                    89.0%[∞](#nt133){ref-type="table-fn"}
                                  Cambodia          Tawfik 2006 [@pmed.1001688-Tawfik1]                        WHO/Cambodia National Treatment Guidelines 2002                                                                               2 districts                        Pharm/DV/CHW                70                       3.0%                                                                                                                                                                               94.0%[±](#nt134){ref-type="table-fn"}  
                                   India             Wylie 2010 [@pmed.1001688-Wylie1]                                Indian National Drug Policy, 2007                        Fever, chills, headache, joint pain   Microscopy/RDT       2 states: region A                         MD                     120   20.0%/40.8%[≠](#nt135){ref-type="table-fn"}                                                  Fever/signs of anaemia[§](#nt126){ref-type="table-fn"}                                                                   14.2%                  
                                                                                                                                                                                                                                          2 states: region B                         MD                     160   48.1%/75.0%[≠](#nt135){ref-type="table-fn"}                                                  Fever/signs of anaemia[§](#nt126){ref-type="table-fn"}                                                                   37.5%                  

Equal numbers used clinical and laboratory tests.

Multiple response answers.

Lower cadre providers (senior and junior community health extension workers and pharmacy technicians).

Higher cadre providers (doctors, nurses, and community health officers).

Used clinical and lab-based tests: 62% sometimes and 26% always.

25.6% used both RDT and microscopy.

Used RDTs only.

Policy document identified by review authors.

Frequency of RDT use: always 9.2%, most of time 33.6%, sometimes 22.7%, rarely 26.1%, never 8.4%.

Microscopy or RDT; 3% used clinical and lab.

Healthcare provider asks about presence of fever/assesses for signs and symptoms of anaemia.

CHW, community health worker; DV, drug vendor/shop; HP, healthcare provider; MA, medical assistant; MD, medical doctor; NA, not reported by study authors; pharm, pharmacist (trained); PSI, Population Services International Research and Metrics; PW, pregnant women.

### Description and frequency of treatment knowledge and practices {#s4b2}

In west and central Africa, 11 studies on health providers were conducted in Nigeria (eight studies), Ghana (two), and CAR (one), where the national antimalarial treatment guidelines stipulate quinine for treatment of uncomplicated malaria in the first trimester and an ACT in the second and third trimesters [@pmed.1001688-KwansaBentum1],[@pmed.1001688-Manirakiza1],[@pmed.1001688-Onwujekwe2] ([Table 10](#pmed-1001688-t010){ref-type="table"}). Only two of the eight studies in Nigeria [@pmed.1001688-Obieche1],[@pmed.1001688-OmoAghoja1]--[@pmed.1001688-Okoro1],[@pmed.1001688-Harrison1],[@pmed.1001688-Enato2],[@pmed.1001688-Okonta1] reported a relatively high proportion of providers adhering to treatment policy. Onwujekwe et al. found that more doctors, pharmacists, and nurses providing ANC services in public than private sector hospitals adhered to the national policy of prescribing ACTs in the second and third trimesters (69% versus 5%); private hospitals predominantly prescribed SP (70%) [@pmed.1001688-Onwujekwe2]. More public than private sector providers prescribed quinine in the first trimester (35% versus 15%); private sector providers predominantly prescribed SP (65%). Okonta found that whilst 56% of doctors had prescribed quinine during the first trimester, the fear of quinine causing miscarriage was a significant consideration, with all but one physician prescribing quinine at lower than the recommended dose, and showing a preference for CQ [@pmed.1001688-Okonta1]. Similarly, Okoro and Nwambu found very low prescription of quinine in the first trimester (2.5%), and ACTs constituted 51% and 29% of antimalarial drugs prescribed in the second and third trimesters, respectively [@pmed.1001688-Okoro1]. Two studies did not stratify treatment drug by trimester [@pmed.1001688-OmoAghoja1],[@pmed.1001688-Harrison1]. Up until 2012, SP continued to be used widely for case management of clinical malaria in pregnancy in Ghana [@pmed.1001688-KwansaBentum1],[@pmed.1001688-SmithPaintain2] and Nigeria [@pmed.1001688-Obieche1],[@pmed.1001688-OmoAghoja1]--[@pmed.1001688-Okoro1],[@pmed.1001688-Harrison1], as well as CQ, despite its known resistance [@pmed.1001688-OmoAghoja1],[@pmed.1001688-Onwujekwe2],[@pmed.1001688-Harrison1], and artemisinin monotherapies [@pmed.1001688-OmoAghoja1],[@pmed.1001688-Harrison1],[@pmed.1001688-Okonta1].

10.1371/journal.pmed.1001688.t010

###### Healthcare provider practices: antimalarials prescribed.
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  Region                          Country                          Study                                               Policy Reference                         Policy Details: Treatment           Scale           Reported Provider Practice                                                                                                                                                                                                                                                  
  ------------------------------ ---------- ---------------------------------------------------- ------------------------------------------------------------- --------------------------- ----------------------- ---------------------------- ----------------------------------------------------------------- ----- --------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------
  **Middle East**                  Yemen         Bin Ghouth 2013 [@pmed.1001688-BinGhouth1]                           WHO guidelines 2010                                  NR                        NR                    11 districts          Clinicians/pharm/drug store employee; structured questionnaire    86                                                                                                                                                                                                   Pre-intervention: AS 47.0%, CQ 19.0%, QN 17.0%; post-intervention: AS 19.0%, CQ 22.0%, QN 60.0%
  **West and Central Africa**       CAR         Manirakiza 2011 [@pmed.1001688-Manirakiza1]                           WHO guidelines 2006                                  QN                        ACT                   \<1 district          ANC staff[≠](#nt137){ref-type="table-fn"}; review of ANC cards    565                         QN 68.6%, ACT 17.1%, AS 11.4%                                               2nd trimester: QN 55.5%, ACT 34.2%, AS 18.8%                         
                                   Ghana      Kwansa-Bentum 2011 [@pmed.1001688-KwansaBentum1]                    Ghana Health Service, 2009                               QN                 AS-AQ/AL/DHA-PPQ              1 district                                   HP; interviews                            88                               QN 45.0%, SP 10.0%,                                                      AS-AQ 45.0%, QN 20.0%, SP 20.0%, AL 5.0%                           
                                                                                                                                                                                                                                                                         DV; interviews                            38          SP 10.0%, QN 5.0%, AL 5.0%, DHA-PPQ 5.0%, AS-AQ 2.0%, AS 1.0%                           DHA-PPQ 10.0%, SP 12.0%, QN 5.0%, AL 5.0%, AS-AQ 3.0%                    
                                   Ghana     Smith Paintain 2011 [@pmed.1001688-SmithPaintain2]                   Ghana Health Service, 2009                               QN                       AS-AQ                  7 districts                                  Midwife/nurse/CHW                          134              Knowledge: QN 50.8%, AS-AQ 20.2%, AS 14.2%, SP 7.5%                                               Knowledge: AS-AQ 78.4%                                    
                                  Nigeria          Obieche 2013 [@pmed.1001688-Obieche1]          National Antimalarial Treatment Guidelines and Policy, 2005              QN                        QN                    \<1 district                 Postpartum women; interview/medical record check           428          SP 38.8%, CQ 14.3%, QN 12.2%, AL 24.5%, AS 8.2%, AS inj. 2%          AL 49.6%, SP 24%, AS 13.4%, AS inj. 2.4%, CQ 4.4%, QN \<1%, AS-SP 1.9%, AS-AQ 1%, AQ 2.4%  
                                  Nigeria         Harrison 2012 [@pmed.1001688-Harrison1]         National Antimalarial Treatment Guidelines and Policy, 2005              QN                        AL                     1 district                         MD; self-administered questionnaire                 123                                                                                                                                                                                                        CQ 22.8%, SP 21.1%, camoquine 10.6%, AL 4.1%, QN, 3.3%, AS 1.6%, camoquine/SP 1.6%
                                  Nigeria           Okonta 2011 [@pmed.1001688-Okonta1]           National Antimalarial Treatment Guidelines and Policy, 2005              QN                        AL                      National                          MD; self-administered questionnaire                 102                CQ 40.2%, QN 19.6%, AQ 14.7%, SP 8.8%, AS 6.9%                                                                                                            
                                  Nigeria            Okoro 2012 [@pmed.1001688-Okoro1]            National Antimalarial Treatment Guidelines and Policy, 2005              QN                        AL                    \<1 district                             HP; medical card reviews                       311                     SP 12.5%, QN 2.5%, ACT 2.5%, CQ 1.25%                                                        ACT 80.0%, QN 1.3%                                      
                                  Nigeria        Onwujekwe 2012 [@pmed.1001688-Onwujekwe2]        National Antimalarial Treatment Guidelines and Policy, 2005              QN                        AL                    \<1 district          Public sector: MD/nurse/pharm; self-administered questionnaire    32                           QN 34.5%, CQ 21.9%, SP 12.5                                                                                                                                                                                   ACT 68.8%, QN 50.0%
                                                                                                                                                                                                                                                 Private sector: MD/nurse/pharm; Self-administered questionnaire   20                          SP 65.0%, QN 15.0%, CQ 15.0%                                                                                                                                                                              SP 70.0%, QN 25.0%, ACT 25.0%
                                  Nigeria            Enato 2012 [@pmed.1001688-Enato2]            National Antimalarial Treatment Guidelines and Policy, 2005              QN                        AL                    \<1 district                                        TBA                                  8                                                                                                                                                                                                                                       Some referred to CQ use
                                  Nigeria             Umar 2011 [@pmed.1001688-Umar1]                                 WHO guidelines 2010                                  QN                        ACT                     1 state                           HP; self-administered questionnaire                 25               SP 68.0%, CQ16.0%, AL 8.0%, SP+CQ 4.0%, QN+CQ 4.0%                                                                                                          
                                  Nigeria        Omo-Aghoja 2008 [@pmed.1001688-OmoAghoja1]       National Antimalarial Treatment Guidelines and Policy, 2005              QN                        AL                      National                          MD; self-administered questionnaire                 84                                                                                                                                                                                                                           CQ 73.0%, SP 10.0%, AS 11.0%, QN 3.0%, AQ 1.0%
  **East and Southern Africa**     Kenya           Kiningu 2013 [@pmed.1001688-Kiningu1]                       National Malaria Guidelines, 2010                 Mild/moderate QN or AL              AL                    \<1 district                                   Medical files                            37                                                                                                                                                                                                                                    QN IV 73.0%, AL 2.7%, QN 2.7%
                                   Malawi        Minyaliwa 2012 [@pmed.1001688-Minyaliwa1]                        Malawi ACT guidelines, 2008                              QN                     AL/AS-AQ                  1 district                                  Pharm; interviews                          22                                    QN 90.9%                                                                            ACT 90.9%                                          
                                  Tanzania       Kamuhabwa 2011 [@pmed.1001688-Kamuhabwa1]                            WHO guidelines 2006                                  QN                        AL                    \<1 district                               Drug dispenser (all)                         200                                   AL 32.8%                                                                                                                               
                                                                                                                                                                                                                                                                      Pharm/mystery client                         60                         QN 55%, SP 19.4%, DHA-PPQ 17.6%                                                                                                                   
                                                                                                                                                                                                                                                                    Pharm Ass/mystery client                       34    QN 16.6%, SP 22.6%, DHA-PPQ 23.5%, AQ 25%, sulphalene-pyrimethamine 33.3%                                                                                              
                                                                                                                                                                                                                                                                    Nurse Ass/mystery client                       71        QN 22.2%, SP 32.5%, DHA-PPQ 23.5%, sulphalene-pyrimethamine 16.6%                                                                                                  
                                                                                                                                                                                                                                                                        DV/mystery client                          35     QN 5.5%, SP 25.9%, DHA-PPQ 33.3%, AQ 75%, sulphalene-pyrimethamine 50%                                                                                                
  **Asia**                        Cambodia          Tawfik 2006 [@pmed.1001688-Tawfik1]                 WHO/Cambodia National Treatment Guidelines 2002             Pf: QN; Pv/Pm: CQ       Pf: ART/MQ; Pv/Pm: CQ          2 districts                           Pharm/DV/CHW; client interviews                   70                                    QN 14.8%                                                                                                                               
  **South America**                Brazil              Luz 2013 [@pmed.1001688-Luz1]                    Brazil malaria treatment guidelines, 2001/2008           Pv: CQ; Pf: QN or QN/CN          AL or MQ                 \>1 district                                  Medical records                           262                                                                                                                                                                           Pv: CQ 91%, CQ combo 2.7%, MQ 2.7%, QN 2.1%, AL 1.6%;Pf: MQ 37.8%, QN+CN 18.9%, QN 13.5%, CQ 8.2%, MQ combo 2.7%, AL 16.2%, ART 1.4%, CN 1.4%

Data obtained from ANC cards.

ART, artemether monotherapy; Ass, assistant; CHW, community health worker; CN, clyndamicine; DHA-PPQ, dihydroartemisinin-piperaquine combination; DV, drug vendor/shop; HP, healthcare provider; inj., injected; MD, medical doctor; MQ, mefloquine; NA, not reported by authors; Pf, *P. falciparum*; pharm, pharmacist; Pm, *P. malariae*; Pv, *P. vivax*; QN, quinine.

In Ghana, Kwansa-Bentum et al. found clinicians prescribing quinine for malaria treatment in the first trimester of pregnancy, per policy, but also SP, and predominantly ACTs were prescribed in the second and third trimesters, though SP and quinine were also prescribed [@pmed.1001688-KwansaBentum1]. In the same study, drug sellers reported pregnant women requesting, in order of preference, SP, ACTs, or quinine, with no difference by trimester. Smith Paintain et al. found that few ANC providers (20%) demonstrated good knowledge of the dosing regimen for treatment in the first trimester, though knowledge that AS-AQ should be prescribed in subsequent trimesters was better (42%), with preference for AS-AQ over quinine due to the side effects and long regimen duration (7 d) of quinine [@pmed.1001688-SmithPaintain2]. In CAR, 29% of ANC cards of women who had delivered in a maternity unit contained at least one antimalarial prescription, of which 57% were for quinine, 27% for ACTs, and 14% for artemisinin monotherapies; 11% and 13% of ACTs and artemisinin monotherapies, respectively, were for treatment in the first trimester [@pmed.1001688-Manirakiza1].

In east and southern Africa, six studies were conducted in Kenya (one study), Malawi (two), Tanzania (one), and Uganda (two), where, again, the national malaria treatment policies recommend quinine in the first trimester, with an ACT (AS-AQ or AL) for the second/third trimester [@pmed.1001688-Malawi1]--[@pmed.1001688-Tanzania1]. In Kenya, while 83% of staff at a provincial hospital stated that they used the national guidelines, guidelines were available at only 25% of points of use, and 73% of pregnant patients received parenteral quinine [@pmed.1001688-Kiningu1]. In Malawi, Kalilani-Phiri et al. found that only 40% of medical doctors and pharmacists knew the treatment guidelines for uncomplicated malaria in pregnant women, compared to 83% for severe malaria [@pmed.1001688-KalilaniPhiri1]. In contrast, Minyaliwa et al. reported that a high proportion (91%) of providers were cognisant of the appropriate drugs to use in each trimester, though specific drug names were not reported [@pmed.1001688-Minyaliwa1]. A study of dispensing practices among private pharmacies in urban Tanzania found low knowledge of appropriate antimalarial drugs, with 33% of providers willing to dispense AL for use in the first trimester and 36% indicating it could not be used in pregnancy. Nevertheless, 82% of women reported that they were asked about gestational age before they were given AL. Pharmacists and nurse assistants had better AL knowledge than pharmaceutical technicians and sales persons [@pmed.1001688-Kamuhabwa1]. In Uganda, Mbonye and Magnussen found that 38% of pregnant women with reported fever but negative blood smears received an antimalarial (drug not specified) in addition to IPTp [@pmed.1001688-Mbonye2].

The remaining studies were conducted in Cambodia (one study) and Brazil (two studies). In Cambodia, only 4/27 pregnant women surveyed received the recommended drug, quinine, in the first trimester, and knowledge amongst private providers about first line treatment for malaria in pregnancy was poor [@pmed.1001688-Tawfik1]. In Brazil, while 93% of patients received the recommended first line therapy for *Plasmodium vivax* malaria, only 45% of patients received the recommended first line therapy for *P. falciparum* malaria, with 7% and 18% of prescriptions, respectively, not sanctioned by national guidelines [@pmed.1001688-Luz2].

### Meta-analysis of adherence to treatment policy {#s4b3}

Frequency data on adherence among healthcare providers to treatment policy by trimester, extracted from 12 studies, showed wide heterogeneity (overall *I* ^2^ 98.6%) ([Figure 4](#pmed-1001688-g004){ref-type="fig"}), and all but one study [@pmed.1001688-Minyaliwa1] were of moderate to high quality. There was lower adherence to treatment policy in the first trimester (28%, 95% CI 14%--47%, nine entries from seven studies) than in the other trimesters (72%, 95% CI 39%--91%, five entries from three studies), and this difference was significant in the sub-group analysis (*p* = 0.02) ([Table S6](#pmed.1001688.s006){ref-type="supplementary-material"}). Studies describing practices among doctors (three entries from Nigeria, 269 doctors in total as defined by the local researchers, all self-administered questionnaires) found that these healthcare providers were significantly less likely to prescribe correctly (11%, 95% CI 4%--23%) than healthcare providers in studies describing practices among other staff or mixed cadres (18 entries, 52%, 95% CI 35%--67%, *p*\<0.001). Studies conducted by self-administered questionnaires showed a significantly lower proportion of adherence to treatment policy (14%, 95% CI 7%--28%, six entries) than studies using interviews (50%, 95% CI 27%--73%, seven entries) or record reviews (66%, 95% CI 39%--86%, eight entries, *p* = 0.001), and studies describing practices in Nigeria were significantly less likely to report correct treatment (25%, 95% CI 12%--46%, ten entries from eight studies) than studies in all other countries combined (58%, 95% CI 40%--75%, 11 entries from eight countries, *p* = 0.018).

![Prevalence of adherence to treatment policy for malaria in pregnancy assessed in 15 studies with quantitative data.\
Pf, *P. falciparum*; Pv, *P. vivax*; self-administered, self-administered questionnaire; MiP, malaria in pregnancy.](pmed.1001688.g004){#pmed-1001688-g004}

### Barriers to effective case management practices for malaria in pregnancy among healthcare providers {#s4b4}

Factors affecting diagnostic and case management practices occurred at all levels of the health system and across all of the health system building blocks ([Table 11](#pmed-1001688-t011){ref-type="table"}). Reliance on clinical diagnosis in the absence of parasitological confirmation by microscopy or RDT is a major weakness to effective management of malaria in pregnancy in many study settings. Parasitological diagnosis was not always possible because of inadequate or lack of diagnostic facilities [@pmed.1001688-Wylie1],[@pmed.1001688-Tawfik1],[@pmed.1001688-Pell1],[@pmed.1001688-KalilaniPhiri1],[@pmed.1001688-Harrison1],[@pmed.1001688-SmithPaintain2] or prohibitive costs to women [@pmed.1001688-Tawfik1],[@pmed.1001688-KalilaniPhiri1]. One study noted concerns among providers about the poor predictive value of microscopy, with providers administering treatment to women with negative blood smears [@pmed.1001688-Mbonye2]. In Cambodia, monovalent RDTs that detected only *P. falciparum* were available at the village level; hence, people with a negative result were reported to self-treat for *P. vivax* [@pmed.1001688-Tawfik1].

10.1371/journal.pmed.1001688.t011

###### Content analysis of barriers to effective case management practices among healthcare providers.
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  Health Systems Building Blocks                 Level                                                                                                        
  ---------------------------------- ----------------------------- ------------------------------------------------------------- --- --- --- --- ---- --- --- ---
  Governance/leadership                        Documents                     Lack of updated policy/training protocols                            4    1      
                                              Supervision                               Lack of supervision                                       3    4      
  Health workforce/human resources           Cadre/persons                         Insufficient number of staff                                   2    2      
                                      Training on case management               Insufficient training for diagnosis                               0    2      
                                                                    Inadequate knowledge of treatment/confusion over guidelines                   10   5      
  Service delivery                             Facility                               Inadequate drug stocks                              2   0               
                                               Diagnosis                           Reliance on clinical symptoms                  9   4                       
                                                                          Inadequate facilities for diagnostic procedures                         5    3      
                                               Treatment                           Patient treatment preference                                            0   1
  Health information systems                District level                         Poor patient history records                           1   1               
                                                                                 Reliance on incomplete ANC cards                         1   0               
  Financing                                  Cost to user                                Cost of diagnosis                                        1    1      
                                                                                         Cost of treatment                                        5    1      
                                                                                 Cost of maintained drug supplies                         1   0               
                                           Cost to provider            Financial incentives to sell certain treatment brands      1   1                       
  Medical products and technology              Diagnosis                  Low perceived efficacy of diagnostic techniques         1   1                       
                                               Treatment                    Low perceived efficacy of treatment options           5   1                       
                                                                          Perception of safety of drugs during pregnancy          4   0                       
                                                                                  Fear of side effects in patient                 6   2                       
                                                                               Risk to patient due to age of patient                                       1   0
                                                                              Risk to patient due to gestational age                                       2   1
                                                                              Fear of growing antimalarial resistance             1   1                       

Numbers indicate the number of studies included in this review that report each factor.

qual, qualitative; quan, quantitative.

Poor knowledge of and adherence to national treatment policy guidelines among healthcare providers was a consistent finding across countries in east [@pmed.1001688-KalilaniPhiri1],[@pmed.1001688-Minyaliwa1] and west Africa [@pmed.1001688-Pell1],[@pmed.1001688-KwansaBentum1],[@pmed.1001688-OmoAghoja1],[@pmed.1001688-Umar1],[@pmed.1001688-Okoro1],[@pmed.1001688-Harrison1],[@pmed.1001688-Enato2],[@pmed.1001688-Okonta1],[@pmed.1001688-SmithPaintain2], Asia [@pmed.1001688-Population1],[@pmed.1001688-Tawfik1], the Middle East [@pmed.1001688-BinGhouth1], and Latin America [@pmed.1001688-Luz2], and knowledge was particularly poor among private providers [@pmed.1001688-Kamuhabwa1],[@pmed.1001688-Onwujekwe2]. In Ghana, healthcare providers asserted that pregnant women were exceptions to the policy of testing prior to treatment, and provided treatment even when a malaria test was negative. This practice was a misinterpretation of the guidelines, which state that in the absence of a laboratory, pregnant women with clinical symptoms of malaria should be treated [@pmed.1001688-Pell1]. Financial incentives and client demand have been reported to motivate private practitioners to sell medicines, even inappropriate medicines or more expensive brands [@pmed.1001688-Okoro1], without parasitological testing [@pmed.1001688-Tawfik1]. Prescription practices were influenced by perceptions of low drug efficacy [@pmed.1001688-Luz2],[@pmed.1001688-OmoAghoja1],[@pmed.1001688-Umar1],[@pmed.1001688-Okonta1], perceptions of increasing drug resistance [@pmed.1001688-Tawfik1],[@pmed.1001688-Umar1], concerns about drug safety [@pmed.1001688-Kamuhabwa1],[@pmed.1001688-OmoAghoja1],[@pmed.1001688-Okonta1], inadequate understanding and fear of potential side effects of drugs in pregnancy [@pmed.1001688-Tawfik1],[@pmed.1001688-Kamuhabwa1],[@pmed.1001688-Okoro1],[@pmed.1001688-Okonta1],[@pmed.1001688-SmithPaintain2],[@pmed.1001688-Minyaliwa1], and the influence of patient preference [@pmed.1001688-Tawfik1], each contributing to poor quality of care. Many of the substandard practices reported are a consequence of factors operating at higher levels of the health system. Lack of national guidelines in India led to healthcare provider confusion about treatment policy [@pmed.1001688-Wylie1]. Elsewhere, lack of training for diagnosis [@pmed.1001688-Population1],[@pmed.1001688-Luz2] and/or treatment [@pmed.1001688-BinGhouth1],[@pmed.1001688-Luz2],[@pmed.1001688-Kiningu1]--[@pmed.1001688-Harrison1],[@pmed.1001688-Minyaliwa1] and lack of supervision [@pmed.1001688-Population1],[@pmed.1001688-Kiningu1],[@pmed.1001688-SmithPaintain2] contributed to poor service delivery. Poor provider knowledge was exacerbated by weak organisation at the level of the health facility, such as inadequate drug stocks [@pmed.1001688-Wylie1], and poor record-keeping practices such as providing written prescriptions and infrequent recording of vital information [@pmed.1001688-Luz2] and clinical findings and diagnoses [@pmed.1001688-Manirakiza1] in both in-patient and out-patient records. Health system policies on fees for diagnosis [@pmed.1001688-Tawfik1],[@pmed.1001688-KalilaniPhiri1] and prescription drugs [@pmed.1001688-Tawfik1],[@pmed.1001688-KwansaBentum1],[@pmed.1001688-Umar1],[@pmed.1001688-Kiningu1],[@pmed.1001688-KalilaniPhiri1],[@pmed.1001688-Okonta1] and human resource constraints [@pmed.1001688-Kiningu1],[@pmed.1001688-SmithPaintain2] also constitute important barriers.

### Determinants of knowledge and diagnostic and treatment practices among healthcare providers {#s4b5}

Determinants of healthcare provider knowledge, diagnostic practices, and treatment practices explored across the different studies included the following: individual healthcare provider factors (cadre, training), type of facility (public or private; primary or tertiary), and region/location ([Table 12](#pmed-1001688-t012){ref-type="table"}). There was insufficient uniformity of indicators and determinants to perform a meta-analysis of pooled data. Cadre of healthcare provider was associated with correct treatment knowledge [@pmed.1001688-SmithPaintain2] and diagnostic practices [@pmed.1001688-Umar1]. Public sector providers were more likely to use clinical diagnosis or parasitological diagnosis with RDTs and to adhere to national guidelines than private providers in Nigeria [@pmed.1001688-Onwujekwe2]. Two studies assessed the impact of training on provider knowledge, finding a significant positive association between provider knowledge and recent training on malaria treatment guidelines [@pmed.1001688-BinGhouth1],[@pmed.1001688-SmithPaintain2].

10.1371/journal.pmed.1001688.t012

###### Determinants affecting provider knowledge of malaria in pregnancy, diagnostic practices, and treatment practices.
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  Factor                                 Determinant                               Study                          Country       Scale       *N*   Effect Measure                                                                                                    Details
  ------------------------------- ------------------------- ---------------------------------------------------- ---------- -------------- ----- ---------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Healthcare provider knowledge             Cadre            Smith Paintain 2011 [@pmed.1001688-SmithPaintain2]    Ghana     7 districts    134         RR                                                                Cadre of staff was not associated with level of knowledge of national treatment guidelines
                                                                                                                                                                                 Those responsible for writing prescriptions were more likely to have correct knowledge of treatment policy for 2nd and 3rd trimesters than those of lower cadres (*p* = 0.06)
                                                                  Harrison 2012 [@pmed.1001688-Harrison1]         Nigeria                   123        Chi2                                                             Cadre of doctor was not associated with awareness of malaria in pregnancy treatment guidelines
                                                                 Omo-Aghoja 2008 [@pmed.1001688-OmoAghoja1]       Nigeria      National     84         Chi2                       Neither level of specialty training nor number of years in practice were associated with knowledge of national guidelines on treatment and prevention with IPTp (*p*\>0.05)
                                                                 Kamuhabwa 2011 [@pmed.1001688-Kamuhabwa1]        Tanzania   \<1 district   200        Chi2                                              No difference in knowledge regarding contraindications of AL in pregnancy between pharmacist and non-pharmaceutical personnel
                                                                                                                                                                                                No difference between pharmacists and non-pharmaceutical personnel concerning knowledge of: quinine, SP, DHA-PPQ; AQ; sulphalene-pyrimethamine
                                                                   Kiningu 2013 [@pmed.1001688-Kiningu1]           Kenya     \<1 district   36     Fisher test                  No difference in awareness or use of malaria in pregnancy clinical guidelines among professional cadres, education levels, or differences in duration of experience (*p*\>0.05)
                                      Public or private          Onwujekwe 2012 [@pmed.1001688-Onwujekwe2]        Nigeria    \<1 district   52         Chi2                                                 No difference between public or private providers in reporting malaria in pregnancy as a serious condition (*p*\>0.05)
                                      Training received      Smith Paintain 2011 [@pmed.1001688-SmithPaintain2]    Ghana     7 districts    134         RR                     Recent attendance at training session resulted in greater knowledge of malaria in pregnancy treatment guidelines (1st trimester, *p* = 0.02; 2nd and 3rd trimesters, *p* = 0.04)
  Diagnostic practices                      Cadre                     Umar 2011 [@pmed.1001688-Umar1]             Nigeria      1 state      25         Chi2                     Exclusive use of clinical features to diagnose malaria in pregnancy was more frequently observed among staff with lower qualifications in primary health centres (*p* = 0.027)
                                      Public or private          Onwujekwe 2012 [@pmed.1001688-Onwujekwe2]        Nigeria    \<1 district   52         Chi2                                                        More public than private providers used symptom recognition to diagnose malaria in pregnancy (*p* = 0.02)
                                                                                                                                                                                                                   No difference in use of microscopy to diagnose malaria in pregnancy between public and private providers
                                                                                                                                                                                                                          More public than private providers used RDTs to diagnose malaria in pregnancy (*p* = 0.04)
                                      Training received          Bin Ghouth 2013 [@pmed.1001688-BinGhouth1]        Yemen     3 districts    86         Chi2        HP training improved the frequency of prescription for quinine use in malaria in pregnancy from 17% to 60% (OR 4.9, *p* = 0.004) and reduced the use of artemether from 47% to 19% (OR 0.26, *p* = 0.01)
                                                             Smith Paintain 2011 [@pmed.1001688-SmithPaintain2]    Ghana     7 districts    134         RR                                       Attendance at a malaria diagnosis workshop was not significantly associated with correct knowledge of treatment for policy for any trimester
                                    Regional differences             Wylie 2010 [@pmed.1001688-Wylie1]             India       2 states     280        Chi2        Between regions, more providers in Chattisgargh used a combination of a presence of fever, blood smear microscopy, signs of anaemia, and haemoglobin levels to diagnose malaria in pregnancy (*p*\<0.001)
  Treatment practices              Type of health facility       Onwujekwe 2012 [@pmed.1001688-Onwujekwe2]        Nigeria    \<1 district   52         Chi2                                                                   More public than private providers prescribed quinine in 1st trimester (*p* = 0.01)
                                                                                                                                                                                                                                   No difference in prescription of CQ between public and private providers
                                                                                                                                                                                                                    More private than public providers prescribed SP for the treatment of malaria in pregnancy (*p*\<0.001)
                                                                       Luz 2013 [@pmed.1001688-Luz1]               Brazil    \>1 district   262        Chi2                         No difference in treatment regimens or in prescriptions containing first choice antimalarials between reference centres for malaria and primary care units (*p*\>0.05)

Chi2, Chi squared test; DHA-PPQ, dihydroartemisinin-piperaquine combination; HP, healthcare provider; OR, odds ratio; RR, adjusted risk ratio.

### Intervention studies {#s4b6}

Only one intervention study was identified, which evaluated the effect of in-service training of clinicians and pharmacists in the private sector in three governorates in Yemen on malaria treatment in pregnant women [@pmed.1001688-BinGhouth1]. The post-training assessment showed improved knowledge of correct dosing, from 17% to 60%, still far short of 100%.

Discussion {#s5}
==========

To our knowledge this review draws together for the first time findings from disparate studies on the treatment-seeking practices for malaria in pregnant women and the case management practices of a range of healthcare providers globally. The key emerging themes are relatively consistent across a range of study settings in terms of local cultural, socio-economic, health system, and non--health system contexts, and geographical locations. One- to three-quarters of women reported malaria illness during pregnancy, of whom treatment was sought by \>85%. Self-medication and traditional healers were reportedly used by 5% to 40% of women, alongside care from the formal health sector (range 42%--92%). Knowledge of drug safety, cost, and perceptions of healthcare services affected treatment choices. Determinants of treatment seeking were education and prior experience of miscarriage or ANC use. Healthcare providers\' reliance on clinical diagnosis and poor adherence to treatment guidelines by trimester were consistently reported. Prescribing practices were driven by poor knowledge of national guidelines and concerns over side effects and drug safety, patient preference, drug availability, and cost. Determinants of provider practices were individual provider factors (cadre, training), facility type (public or private; primary or tertiary), and sub-national region.

The review highlights important limitations in the implementation of the WHO policy on treatment of malaria in pregnancy [@pmed.1001688-World1],[@pmed.1001688-World2]. There is an apparent disconnect between the theories that underpin WHO policy and the beliefs and attitudes of women, in addition to which there is dissonance between the principles of delivery of quality care, and the experiences and practices of pregnant women and healthcare providers ([Figure 5](#pmed-1001688-g005){ref-type="fig"}). Importantly, women do not uniformly seek care within the formal health system, and when they do, they may not access appropriate diagnosis and treatment, because of poor healthcare provider skills or inadequate resources or because they cannot afford to pay for the services.

![Integration of findings in relation to WHO case management policy [@pmed.1001688-World1].\
LBW, low birth weight.](pmed.1001688.g005){#pmed-1001688-g005}

Barriers to access among women---in particular, poor knowledge of drug safety, prohibitive costs, and self-treatment practices---suggest ministries of health need to improve women\'s access to information so that they can make informed choices. Educating women about the risks of malaria in pregnancy will be important, especially as the manifestation of malaria illness in pregnancy may be confused with pregnancy-related symptoms [@pmed.1001688-Pell2]. Even when women think they have malaria, a series of socio-cultural factors impede women\'s ability to act, such as not wishing to disclose their pregnancy status and other factors operating at the household level that restrict women\'s autonomy to seek care, as reported by others [@pmed.1001688-Tawfik1],[@pmed.1001688-Pell2],[@pmed.1001688-Finlayson1]. The finding that pregnant women may self-treat for malaria was partly attributed by the reviewed studies to the irregular and inadequate supply of drugs at health facilities. Given that alternative care providers include shop vendors (who are poorly informed or otherwise incentivised to give more expensive and sometimes inappropriate drugs) and TBAs (who practice and promote herbal remedies and traditional herbs as healthier or less risky to the developing foetus) [@pmed.1001688-Stangeland1], women need appropriate information about which antimalarials are recommended and safe to use for the treatment of malaria at different stages of pregnancy. Advertising provides an opportunity for governments to add messages about safety and use of antimalarials in pregnancy, and information pamphlets could be given to women at ANC facilities. One of the main barriers to women seeking treatment for malaria at formal health facilities is cost, both direct costs such as user fees and indirect costs, as has been reported in studies on antenatal care seeking more broadly [@pmed.1001688-Johnson1],[@pmed.1001688-Perkins1]. The economic barriers to accessing expensive diagnostic tests and treatment for malaria among pregnant women have been reported previously [@pmed.1001688-Worrall1] and warrant a review of strategies to reach pregnant women with safe and affordable treatment options.

Diagnosis of malaria in pregnancy in many settings is challenging. In stable and high transmission settings, parasitological diagnosis based on microscopy or RDTs potentially reduces the unnecessary use of antimalarials in pregnancy, particularly in areas of high HIV prevalence, where HIV-infected patients have a high incidence of febrile illness [@pmed.1001688-World2]. As our review shows, the reality in resource-constrained public health facilities and among community providers is that diagnosis is frequently restricted to clinical symptoms. As observed in a clinical study among pregnant women in Mozambique, the positive predictive values of the three most common malaria symptoms---headache, arthromyalgias, and history of fever---for malaria parasitaemia were low (28%, 29%, and 33%, respectively) [@pmed.1001688-Bardaji1]. Even where diagnostic tests are available, studies reported that providers sometimes choose to ignore negative test results and prescribe antimalarials when malaria is suspected. The reasons for ignoring diagnostic test results are likely to be a combination of factors related to user preferences and demand, suspected insensitivity or inferiority of the tests, inferior reagents, or lack of trust in the accuracy of slide reading by laboratory staff. Efforts are needed to scale up the availability of RDTs at points of care used by pregnant women and to improve provider proficiency in their application.

Healthcare providers from a range of countries and continents and across a variety of cadres in the private and public sectors, and formal and informal sectors, demonstrated poor knowledge of and adherence to national treatment policy guidelines. Poor knowledge of and availability of treatment guidelines, and concerns over side effects and drug safety suggest the need for refresher training, job aids, and improved supervision. The finding that doctors were less likely to prescribe correctly may reflect personal judgements based on knowledge or individual client needs, as noted in a study in Zimbabwe where many practitioners felt that guidelines would limit their personal flexibility in caring for patients [@pmed.1001688-Bhagat1]. Health system strengthening is needed to improve drug availability, as well as legislation to promote rational drug use to eliminate the use of monotherapies and other non-recommended antimalarials across all service providers. Efforts by ministries of health to incorporate private sector providers into centralised training and dissemination activities on national treatment policy are needed. In addition, a licensing system to regulate which antimalarials are sold at the community level is needed to prohibit the use of monotherapies and to reduce women\'s exposure to ineffective drugs and the potential risks of ACT use in the first trimester.

With the advent of the 2006 WHO policy [@pmed.1001688-World2], inadvertent exposure to ACTs among pregnant women in the first trimester has been a considerable public health concern [@pmed.1001688-Ward1],[@pmed.1001688-Crawley1]. Few studies in our review stratified antimalarial use by trimester; of those that did, prescription of ACTs in the first trimester was reported in Ghana, CAR, and Nigeria. This is a very real concern, and research by the Malaria in Pregnancy Consortium is ongoing to develop pharmacovigilance systems that can be implemented in resource-poor countries to monitor the safety of antimalarials in pregnancy, including inadvertent exposures in the early first trimester [@pmed.1001688-Dellicour1]. The continued use of drugs that are no longer recommended in national treatment policies, such as SP (recommended for IPTp only) in Ghana and Nigeria, and CQ in Nigeria (because of known high levels of parasite resistance to CQ) [@pmed.1001688-Bloland1], is another area for concern. The use of artemisinin monotherapies is a major threat for the development of artemisinin resistance in the Africa region, as occurred in parts of Asia [@pmed.1001688-World4],[@pmed.1001688-Fairhurst1].

The dearth of implementation research on interventions to improve the quality of case management of malaria in pregnancy underscores the fact that this is a neglected area of research, despite case management constituting one of the three key strategies for controlling malaria in pregnancy in sub-Saharan Africa, and a lifesaving intervention for both mother and child in lower transmission settings in Asia and Latin America. Research using standardised methodologies is needed to systematically document treatment seeking in pregnant women and healthcare provider practices across a range of countries and settings. Implementation research is needed to evaluate the impact of strengthened public sector practices on pregnant women\'s access to malaria treatment in the public sector, as well as strategies that target private drug sellers, such as better information, communication, and legislation for rational drug use.

Strengths and Limitations {#s5a}
-------------------------

The review uses data from quantitative, qualitative, and mixed methods studies to increase the comprehensiveness of the review; studies with quantitative data provided frequencies of practices, the qualitative data provided important explanatory factors driving those behaviours, and the content analysis was useful to determine the frequency of reporting of the different factors associated with case management of malaria in pregnancy across studies. We did not attempt a meta-ethnography, as has been done by others [@pmed.1001688-Pell2]. The primary geographic scope of the review is Africa, since this is where the majority of the included studies were undertaken, with few available studies in Asia and Latin America. Whilst no restrictions were placed on the language, and no studies were excluded on the basis of language, the focus of the Malaria in Pregnancy Library (the primary source of studies) to date has been the European family of languages, predominantly English. Reviewer bias was limited by the use of two reviewers to independently assess inclusion criteria. The reporting of the included studies was assessed for quality, and reporting quality for the majority of studies was assessed to be moderate to high. Findings from five studies [@pmed.1001688-Maiga1],[@pmed.1001688-Kamuhabwa1],[@pmed.1001688-Enato2],[@pmed.1001688-Minyaliwa1],[@pmed.1001688-Mbonye2] assessed to be of low quality (meeting \<50% of the quality criteria) were consistent with the other studies. Inconsistency in study methodologies and end points precluded a meta-analysis of pooled data of the determinants of women\'s access to treatment or healthcare provider case management practices. In the meta-analysis for source of treatment, there may have been overlap between sources of treatment reported, e.g., a doctor may practice in a health facility, antenatal clinic, or private clinic.

The majority of studies of women were undertaken at sub-district, district, or state level, which limits the generalisability of the individual studies. There was reasonable consistency of findings across different studies in the same country and across studies in different countries. The studies of healthcare providers had greater geographic scope, with eight of 18 studies undertaken in more than one district or state, three of which were done at national level.

Conclusions {#s6}
===========

Our review highlights the poor quality of case management practices for malaria in pregnancy across many parts of Africa, Asia, and Latin America. These practices not only threaten the health outcomes for mothers and their infants, but endanger the prospective useful life of several therapeutic drugs, in particular the artemisinins, through the continued use of monotherapies. The challenge for ministries of health will be the deployment of legislative and quality improvement interventions to reach the broad range of healthcare providers that administer antimalarial drugs in the community, in the private and public sectors as well as in the formal and informal sectors. Further implementation research using standardised methodologies is needed to systematically assess the extent of substandard case management practices at the national scale, to review how policies are implemented and disseminated by countries, and to assess practitioner and patient adherence. Research to evaluate targeted or multifaceted interventions aimed to improve the delivery of and access to quality case management services for pregnant women should be a priority.
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ACT

:   artemisinin-based combination therapy

AL

:   artemether-lumefantrine

ANC

:   antenatal care

AQ

:   amodiaquine

AS

:   artesunate

CAR

:   Central African Republic

CHW

:   community health worker

CQ

:   chloroquine

IDP

:   internally displaced person

IPTp

:   intermittent preventive treatment in pregnancy

RDT

:   rapid diagnostic test

SP

:   sulphadoxine-pyrimethamine

TBA

:   traditional birth attendant
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